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Aminocarboxylic acids related to
aspergillomarasmine A (AMA) and
ethylenediamine-N,N0-disuccinic acid (EDDS) are
strong zinc-binders and inhibitors of the metallo-
beta-lactamase NDM-1†
Kamaleddin H. M. E. Tehrani,‡a Haigen Fu,‡b Nora C. Brüchle, a Vida Mashayekhi,c
Alejandro Prats Luján, b Matthijs J. van Haren,a Gerrit J. Poelarends *b and
Nathaniel I. Martin *a
A series of aminocarboxylic acid analogues of aspergillomarasmine A
(AMA) and ethylenediamine-N,N’-disuccinic acid (EDDS) were chemoen-
zymatically synthesized via the addition of various mono- and diamine
substrates to fumaric acid catalyzed by the enzyme EDDS lyase. Many of
these novel AMA and EDDS analogues demonstrate potent inhibition of
the bacterial metallo-b-lactamase NDM-1. Isothermal titration calori-
metry assays revealed a strong correlation between the inhibitory
potency of the compounds and their ability to bind zinc. Compounds
1a (AMA), 1b (AMB), 5 (EDDS), followed by 1d and 8a, demonstrate the
highest synergy with meropenem resensitizing an NDM-1 producing
strain of E. coli to this important carbapenem of last resort.
Antibiotic resistance is a global public health concern with an
increasing economic burden.1,2 Among Gram-negative pathogens,
b-lactam resistance due to the production of b-lactamases is a
major cause of antibiotic resistance.3 Based on their mechanism
of b-lactam hydrolysis, b-lactamases can be classified as serine- or
metallo-b-lactamases (SBLs and MBLs respectively). While SBLs
hydrolyze b-lactams via an active site serine nucleophile, MBLs do
so via a water molecule coordinated with active site zinc ion(s).4
Although there are clinically used SBL inhibitors available to
counteract the infections caused by SBL-producing bacteria,5
there are currently no approved MBL inhibitors available.
Recent screening efforts led to the identification of
aspergillomarasmine A (AMA, 1a, Table 1) as a potent inhibitor
of the clinically relevant NDM- and VIM-type MBLs.6 This finding
was followed by reports describing the chemical synthesis of AMA
and its structural analogues.7–11 Among them, synthetic routes
using either a key N-nosyl protected aziridine intermediate10 or a
cyclic sufamidate9 furnished AMA in relatively few steps and the
highest reported yields (overall yields of 28% and 19% respectively).
Recently, we reported that ethylenediamine-N,N0-disuccinic acid
(EDDS) lyase naturally catalyzes a reversible two-step sequential
addition of ethylenediamine (2) to two molecules of fumaric acid
(3), giving (S)-N-(2-aminoethyl)aspartic acid (AEAA, 4) as an inter-
mediate and (S,S)-EDDS (5) as the final product (Table 1A).12
EDDS lyase was subsequently found to have broad substrate
promiscuity,13–15 accepting a wide range of amino acids with
terminal amino groups (6a–k) for regio- and stereoselective
addition to fumarate, thus providing a straightforward bio-
catalytic method for the asymmetric synthesis of AMA (1a), AMB
(1b), and related aminocarboxylic acids (1c–k, Table 1B).13 To
further explore the substrate scope of EDDS lyase, as well as to
prepare a small library of EDDS derivatives as potential NDM-1
inhibitors,16 we here describe the EDDS-lyase catalyzed reaction of
fumaric acid with various diamines containing different aliphatic
linkers between the two amino functional groups (7a–i) (Table 2).
Interestingly, diamine substrates with two to four atoms between
the two amino groups (7a–g) were well accepted as substrates by
EDDS lyase, giving good conversions (47–83%) and yielding the
corresponding aminocarboxylic acid products (8a–g) in 21–60%
isolated yield (Table 2, entries 1–7). Hence, EDDS lyase has a
broad diamine scope, allowing the two-step sequential addition
of appropriate diamines to fumaric acid, providing a powerful
synthetic tool for the preparation of valuable aminocarboxylic
acids. Conversely, the elongated diamines with five atoms
between the two amino groups (7h–i) were not accepted as
substrates by EDDS lyase (Table 2, entries 8 and 9).
The ability of the AMA and EDDS analogues to inhibit NDM-1
was evaluated using a fluorescence-based assay previously
described by Schofield and coworkers.17 This assay makes use
of a cephalosporin substrate known as FC5 which upon
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hydrolysis releases 7-hydroxycoumarin. The well characterized
NDM-1 inhibitors AMA, EDTA, and dipicolinic acid (DPA) were
used as positive controls. In general, most of the AMA and
EDDS analogues tested showed potent activity against NDM-1
with IC50 values ranging from 1.3 mM to 18.3 mM (Table 3).
Compared with its analogues 8a–g, EDDS (5) proved to possess
the highest activity (IC50 = 2.21 mM). Modifications to the central
aliphatic spacer in length or steric bulk (or both) were generally
tolerated. However, elongation of the linker to four methylene units
(8g) led to the complete loss of activity. The inhibitory activity of the
naturally occurring AMB (1b) was also promising (IC50 = 2.63 mM).
Insertion of a methylene group as in compounds 1c and 1d
maintained the activity leading to equipotent new AMB analogues.
Toxin A (1e) is believed to be the biosynthetic precursor
of the related fungal aminocarboxylic acid AMA and AMB.18
We found low IC50 values for toxin A (1e) and its diastereomer
1f (IC50 = 2.33 mM and 2.89 mM respectively). Replacing the
diaminopropionic acid moiety with the much simpler glycine unit
as in 1j led to a slight reduction of potency. Notably, elongation of
the aliphatic spacers in both 1e and 1j, to generate compounds
1g–i and 1k, resulted in further or complete loss of NDM-1
inhibitory activity.
The majority of MBL inhibitors reported to date owe their
activity to an ability to bind zinc. In general, MBL inhibitors
either coordinate with zinc ions within the MBL active site or,
if they are strong enough chelators, actively strip zinc from
the MBL active site rendering the enzyme inactive.19,20 We
have previously shown that the zinc-binding capacity of MBL
inhibitors can be conveniently quantified using isothermal
titration calorimetry (ITC).21 To this end, we next measured the
zinc-binding affinity of the aminocarboxylic acids analogues
listed in Table 3. These studies were conducted by titrating a
zinc-containing solution into the test compound with the heat of
binding monitored using a microcalorimeter (see supplementary
information for more detail). The relevant thermodynamic para-
meters thus obtained (Kd and DH) are presented in supplemental
Table S1. For compounds 1e–f, 1j, and 8c strong zinc binding
was established with Kd values in the nM range. Notably, in the
case of compounds 1b–d, 5, 8a, 8b, 8d, 8e, and 8f, the zinc
binding interactions were found to be so strong (Kd o 100 nM)
Table 1 Stereoselective C–N bond-formation reactions catalyzed by
EDDS lyase
(A) Natural reaction catalyzed by EDDS lyase. (B) Previously reported12,13
analogues of AMA, AMB, and toxin A prepared using the EDDS lyase
methodology and here investigated as NDM-1 inhibitors.
Table 2 Enzymatic synthesis of EDDS analoguesa
a Conditions and reagents: reaction mixture (15 mL) consisted of
fumaric acid (3, 60 mM), a diamine substrate (7a–i, 10 mM) and
purified EDDS lyase (0.05 mol% based on diamine) in 50 mM Na2HPO4
buffer (pH 8.5). The reaction mixture was incubated at room tempera-
ture for 48 h (7a–e and 7g) or 96 h (7f and 7h–i). b Absolute stereo-
chemistry of products not determined. c Conversion yields based on
comparing 1H NMR signals of substrates and corresponding products.
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that only DH values could be accurately determined. By com-
parison, for 1h, 1i, 1k, and 8g the zinc binding was too weak to
allow for a reliable determination of any thermodynamic para-
meters. The data thus obtained reveals a clear correlation
between zinc-binding affinity and the IC50 values measured
against NDM-1. These findings indicate that the major mecha-
nism of NDM-1 inhibition for the aminocarboxylic acids here
studied can be attributed to their ability to bind zinc.
The compounds were also tested for their ability to resensi-
tize an NDM-1 producing E. coli isolate to meropenem, a
clinically important carbapenem antibiotic. This NDM-1
expressing strain of E. coli was found to be highly resistant to
carbapenem antibiotics with a minimum inhibitory concen-
tration (MIC) of 32 mg mL1 for meropenem. As a measure of
potency, we determined the ‘‘rescue concentration’’ of each test
compound (see ESI,† Table S2) which provides an indication of
synergy.9 Rescue concentration is defined as the lowest concen-
tration of an MBL inhibitor that can resensitize a resistant
strain to the antibiotic of interest when applied at its clinical
breakpoint concentration (1 mg mL1 for meropenem). In
addition, the fractional inhibitory concentration index (FICI)
values were determined for each compound and are provided in
Table 3. FICI values were established by applying the following





Among the EDDS analogues examined, 5 followed by 8a were
among the most potent synergizers. AMB (1b) and its related
analogues 1c and 1d also showed potent to moderate activity.
Interestingly, neither toxin A or its analogues (1e–k) demonstrated
potent synergistic activity suggesting they may not be able to
effectively access the enzyme target in the microorganism.
In conclusion, we here describe the application of a robust
chemoenzymatic synthesis route in the preparation of a series of
novel aminocarboxylic acids. A number of these compounds
were found to be potent inhibitors of NDM-1, with inhibitory
activities well correlated to zinc binding ability. In addition, a
number of the most active compounds demonstrated promising
synergistic activity against an NDM-1 producing E. coli when
combined with meropenem. In the search for new agents to
combat antibiotic resistance, chemoenzymatic methodologies
such as those here described have the potential to provide access
to novel inhibitors of metallo-b-lactamases of clinical relevance.
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Table 3 Activity of AMA and EDDS analogues against NDM-1 and an
E. coli strain producing the same enzyme
Compound IC50
a (mM) FICIb,c
1a (AMA) 0.94  0.11 0.063
1b (AMB) 2.63  0.10 0.063
1c 1.35  0.12 0.156
1d 1.37  0.04 0.094
1e 2.33  0.18 40.281
1f 2.89  0.24 40.281
1g 18.34  3.67 40.281
1h 4400 40.281
1i 4400 40.281
1j 7.87  0.29 40.281
1k 4400 40.281
5 (EDDS3Na) 2.21  0.39 0.047
8a 4.33  0.11 0.094
8b 9.65  0.16 0.281
8c 3.11  0.19 40.281
8d 2.85  0.10 40.281
8e 3.50  0.16 40.281
8f 2.85  0.04 0.156
8g 4400 40.281
EDTA2Na 1.25  0.06 0.047
DPA 4.94  0.22 0.094
a The half-maximal inhibitory concentration of the compounds tested
against NDM-1 using FC5 as substrate. b FICI: fractional inhibitory
concentration index. FICI o 0.5 indicates synergy (see main text for
formula used to calculate FICI). c The test microorganism was E. coli
RC0089, an NDM-1 positive patient isolate with an MIC for meropenem
of 32 mg mL1.
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